Patents by Inventor Anand C. Burman
Anand C. Burman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8927023Abstract: The invention relates to a biocompatible, non-biodegradable, and non-toxic polymer of formula (I), comprising of three monomeric units, selected from 1-Vinylpyrrolidne (VP), N-Isopropylactylamide (NIPAM), and ester of Maleic anhydride and Polyethylene glycol (MPEG), cross-linked with a bi-functional vinyl derivative, of high purity and substantially free of respective toxic monomeric contaminants, and a process for preparation thereof. The invention further relates to nanoparticulate pharmaceutical compositions of poorly water-soluble drugs or compounds comprising the polymer of the invention, which are safe, less-toxic and convenient for bedside administration to patients in need thereof. Furthermore, the invention relates to a highly selective method for preparation of nanoparticulate pharmaceutical compositions of poorly water-soluble drugs or compounds.Type: GrantFiled: October 2, 2012Date of Patent: January 6, 2015Assignee: Fresenius Kabi Oncology LimitedInventors: Anand C. Burman, Rama Mukherjee, Dhiraj Khattar, Sanjoy Mullick, Manu Jaggi, Manoj Kumar Singh, Mukesh Kumar, Deepak Prusthy, Pawan Kumar Gupta, Rajendran Praveen, Shobhit Singh
-
Publication number: 20130274211Abstract: The invention relates to a biocompatible, non-biodegradable, and non-toxic polymer of formula (I), comprising of three monomeric units, selected from 1-Vinylpyrrolidne (VP), N-Isopropylactylamide (NIPAM), and ester of Maleic anhydride and Polyethylene glycol (MPEG), cross-linked with a bi-functional vinyl derivative, of high purity and substantially free of respective toxic monomeric contaminants, and a process for preparation thereof. The invention further relates to nanoparticulate pharmaceutical compositions of poorly water-soluble drugs or compounds comprising the polymer of the invention, which are safe, less-toxic and convenient for bedside administration to patients in need thereof. Furthermore, the invention relates to a highly selective method for preparation of nanoparticulate pharmaceutical compositions of poorly water-soluble drugs or compounds.Type: ApplicationFiled: October 2, 2012Publication date: October 17, 2013Applicant: Fresenius Kabi Oncology LimitedInventors: Anand C. Burman, Rama Mukherjee, Dhiraj Khattar, Sanjoy Mullick, Manu Jaggi, Manoj Kumar Singh, Mukesh Kumar, Deepak Prusthy, Pawan Kumar Gupta, Rajendran Praveen, Shobhit Singh
-
Patent number: 8338562Abstract: The invention relates to a biocompatible, non-biodegradable, and non-toxic polymer of formula (I), comprising of three monomeric units, selected from 1-Vinylpyrrolidone (VP), N-Isopropylacrylamide (NIPAM), and ester of Maleic anhydride and Polyethylene glycol (MPEG), cross-linked with a bi-functional vinyl derivative, of high purity and substantially free of respective toxic monomeric contaminants, and a process for preparation thereof. The invention further relates to nanoparticulate pharmaceutical compositions of poorly water-soluble drugs or compounds comprising the polymer of the invention, which are safe, less-toxic and convenient for bedside administration to patients in need thereof. Furthermore, the invention relates to a highly selective method for preparation of nanoparticulate pharmaceutical compositions of poorly water-soluble drugs or compounds.Type: GrantFiled: December 26, 2006Date of Patent: December 25, 2012Assignee: Fresenius Kabi Oncology LimitedInventors: Anand C. Burman, Rama Mukherjee, Dhiraj Khattar, Sanjoy Mullick, Manu Jaggi, Manoj Kumar Singh, Mukesh Kumar, Deepak Prusthy, Pawan Kumar Gupta, Rajendran Praveen, Shobhit Singh
-
Patent number: 8022055Abstract: The invention relates to novel betulinic acid derivatives of formula (I), wherein R is C(?CH2)CH3 or CH(CH3)2; R2 together with the adjacent carbonyl group forms a carboxylic acid, carboxylic acid ester or amide or substituted amide; R3 or R4 are hydrogen or aryl with the proviso that both are not independently hydrogen or alkyl or R3 and R4 are combined together to form an aryl ring optionally substituted with a group X, wherein X is selected from halogen, alkyl, cyano, nitro, alkoxy, amino or substituted amine; Y is N or O; and R1 is zero when Y is O, and R1 is hydrogen, alkyl or aryl alkyl when Y is N, useful for inhibition of tumor cancer cells.Type: GrantFiled: December 29, 2005Date of Patent: September 20, 2011Assignee: Dabur Pharma LimitedInventors: Rama Mukherjee, Sanjay Kumar Srivastava, Mohammad Jamshed Ahmed Siddiqui, Manu Jaggi, Anu T. Singh, Anand Vardhan, Manoj Kumar Singh, Praveen Rajendran, Hemant Kumar Jajoo, Anand C. Burman, Vivek Kumar, Nidhi Rani, Shiv Kumar Agarwal
-
Patent number: 7781398Abstract: The present invention relates to a combination of peptides that may be used for treatment of cancer. The peptide combination competes for the binding of specific neuropeptides at the plasma membrane and thereby alters the levels of key intracellular molecules implicated in cell proliferation, resulting in a broad spectrum of anticancer activity. The invention also relates to pharmaceutical compositions containing a combination of such peptide analogs.Type: GrantFiled: December 21, 2006Date of Patent: August 24, 2010Assignee: Dabur Pharma Ltd.Inventors: Rama Mukherjee, Anand C. Burman, Anu T. Singh, Manu Jaggi, Sudhanand Prasad, Sarjana Dutt
-
Patent number: 7699987Abstract: A stabilized pharmaceutical composition of anticancer drug and a solvent like Polyethoxylated castor oil (cremophor) also containing any other suitable solubilizer suitable for human administration like dehydrated alcohol, is disclosed. Compositions prepared using this purified polyethoxylated castor oil enhance the stability of paclitaxel in such compositions.Type: GrantFiled: June 8, 2006Date of Patent: April 20, 2010Assignee: Dabur Pharma Ltd.Inventors: Anand C. Burman, Rama Mukherjee, Dinesh Kumar, Dhiraj Khattar, Mukesh Kumar, Praveen Khullar, Perundurai S. Srinivasan, Rajesh Srivastava
-
Patent number: 7674824Abstract: A storage stable pharmaceutical composition comprising a solution of Oxaliplatin in water and a catalytic amount of a carbohydrate. A process for forming such pharmaceutical composition comprising dissolving a known amount of Oxaliplatin in water; adding an amount of carbohydrate in the range of 0.0010% to 0.05% w/v with respect to such solution; agitating the mixture to get clear solution; filtering it through a filter membrane under aseptic conditions; and filling the solution resulting into glass vials sealed with elastomeric stoppers and aluminium flip-off seals.Type: GrantFiled: September 5, 2006Date of Patent: March 9, 2010Assignee: Fresenius Kabi Oncology LimitedInventors: Satish Chandra Upadhyay, Manoj Kumar Pananchukunnath, Ajeet Kumar Singh, Deepti Jain, Deepak Judgelal Parshotamdas, Rama Mukharjee, Anand C Burman
-
Publication number: 20090318661Abstract: The invention relates to a biocompatible, non-biodegradable, and non-toxic polymer of formula (I), comprising of three monomeric units, selected from 1-Vinylpyrrolidone (VP), N-Isopropylacrylamide (NIPAM), and ester of Maleic anhydride and Polyethylene glycol (MPEG), cross-linked with a bi-functional vinyl derivative, of high purity and substantially free of respective toxic monomeric contaminants, and a process for preparation thereof. The invention further relates to nanoparticulate pharmaceutical compositions of poorly water-soluble drugs or compounds comprising the polymer of the invention, which are safe, less-toxic and convenient for bedside administration to patients in need thereof. Furthermore, the invention relates to a highly selective method for preparation of nanoparticulate pharmaceutical compositions of poorly water-soluble drugs or compounds.Type: ApplicationFiled: December 26, 2006Publication date: December 24, 2009Applicant: Dabur Pharma LimitedInventors: Anand C. Burman, Rama Mukherjee, Dhiraj Khattar, Sanjoy Mullick, Manu Jaggi, Manoj Kumar Singh, Mukesh Kumar, Deepak Prusthy, Pawan Kumar Gupta, Rajendran Praveen, Shobhit Singh
-
Publication number: 20090017105Abstract: Concentrates or proliposomal compositions of poorly water-soluble drugs and compounds, comprising of one or more membrane forming lipids, a membrane stabilizing agent, in a suitable vehicle, and optionally containing a Polyethylene Glycol (PEG)-coupled phospholipid or a mixture thereof and further, optionally containing pharmaceutically acceptable excipients such as antioxidants, buffering agents, acidifying agents etc. are provided, which have superior long term stability. The concentrates of proliposomal compositions instantly form liposomes of the said poorly water-soluble drugs and compounds on rapid injection to a diluting fluid, the liposomal composition so obtained, characterized by a physical stability more than 24 hours, ?95% drug encapsulation and having a particle size diameter of less than 100 nm. The liposomal compositions so obtained can further be directly administered to patients in need of treatment of the poorly water-soluble drugs and compounds.Type: ApplicationFiled: March 11, 2008Publication date: January 15, 2009Inventors: Dhiraj Khattar, Mukesh Kumar, Rama Mukherjee, Anand C. Burman, Minakshi Garg, Manu Jaggi, Anu T. Singh, Anshumali Awasthi
-
Publication number: 20080293682Abstract: The invention relates to novel betulinic acid derivatives of formula (I), wherein R is C(?CH2) CH3 or CH(CH3)2; R2 together with the adjacent carbonyl group forms a carboxylic acid, carboxylic acid ester or amide or substituted amide; R3 or R4 are hydrogen or aryl with the proviso that both are not independently hydrogen or alkyl or R3 and R4 are combined together to form an aryl ring optionally substituted with a group X, wherein X is selected from halogen, alkyl, cyano, nitro, alkoxy, amino or substituted amine; Y is N or O; and R1 is zero when Y is O, and R1 is hydrogen, alkyl or aryl alkyl when Y is N, useful for inhibition of tumor cancer cells.Type: ApplicationFiled: December 29, 2005Publication date: November 27, 2008Inventors: Rama Mukherjee, Kumar Srivastava, Mohammad Jamshed Ahmed Siddioui, Manu Jaggi, Anu T. Singh, Anand Vardhan, Manoj Kumar Singh, Praveen Rajendran, Hemant Kumar Jajoo, Anand C. Burman, Vivek Kumar, Nidhi Rani, Shiv Kumar Agarwal
-
Patent number: 7179937Abstract: The invention relates to the use of derivatives of cyclopentenone for the inhibition or prevention of the growth or multiplication of cancer cells, and to therapeutic compositions containing such compounds. The invention relates more specifically to the use of derivatives of cyclopentenone for the inhibition and/or prevention of cancer of the colon, pancreas, larynx, ovary, duodenum, kidney, oral cavity, prostate, lung, endothelial cells and leukemias.Type: GrantFiled: December 4, 2002Date of Patent: February 20, 2007Assignee: Dabur Research FoundationInventors: Mukund K. Gurjar, Radhika D. Wakharkar, Gautam R. Desiraju, Ashwini Nangia, Jhillu Singh Yadav, Anand C. Burman, Rama Mukherjee, Hanumant Bapu Rao Borate, Srivari Chandrasekhar, Manu Jaggi, Anuo T. Singh, Kamal Kapoor, Sanjay Sarkhel, K. V. V. M. Sairam
-
Patent number: 7173006Abstract: The present invention relates to a combination of peptides that may be used for treatment of cancer. The peptide combination competes for the binding of specific neuropeptides at the plasma membrane and thereby alters the levels of key intracellular molecules implicated in cell proliferation, resulting in a broad spectrum of anticancer activity. The invention also relates to pharmaceutical compositions containing a combination of such peptide analogs.Type: GrantFiled: December 23, 2002Date of Patent: February 6, 2007Assignee: Dabur Research FoundationInventors: Rama Mukherjee, Anand C. Burman, Anu T. Singh, Manu Jaggi, Sudhanand Prasad, Sarjana Dutt
-
Patent number: 7094755Abstract: The present invention encompasses novel analogs of vasoactive intestinal peptide (VIP), containing substitutions at appropriately selected amino acids. The invention particularly relates to the design and synthesis of novel biologically active VIP analogs containing ?, ?-dialkylated amino acids in a site-specific manner. Specifically, the invention relates to the synthesis of VIP peptide derivatives, which bind selectively to VIP receptors on target cells. The invention encompasses methods for the generation of these peptides, compositions containing the peptides and the pharmacological applications of these peptides especially in the treatment and prevention of cancer.Type: GrantFiled: September 25, 2002Date of Patent: August 22, 2006Assignee: Dabur Research FoundationInventors: Anand C. Burman, Sudhanand Prasad, Rama Mukherjee, Anu T. Singh, Archna Mathur, Neena Gupta
-
Patent number: 7060678Abstract: Anticancer peptides which incorporate furanoid sugar amino acids and compositions made using these peptides are described. Methods for synthesis of the peptides and for preparing the furanoid sugar amino acids are disclosed. The peptides and compositions made using the peptides have pharmacological applications of these peptides especially in the treatment and prevention of cancer and tumors.Type: GrantFiled: August 8, 2003Date of Patent: June 13, 2006Assignee: Dabur Research FoundationInventors: Sudhanand Prasad, Tushar Kanti Chakraborty, Archna Mathur, Manu Jaggi, Ajit Chand Kunwar, Rama Mukherjee, Anand C. Burman
-
Patent number: 6989371Abstract: The present invention encompasses novel peptides that are antagonists to bombesin and bombesin like peptides and are useful in the treatment of cancer. The invention particularly relates to the design and synthesis of the novel peptides incorporating ?,?-amino acids in a site specific manner. The invention encompasses methods for the generation of these peptides, compositions containing the peptides and the pharmacological applications of these peptides especially in the treatment and prevention of cancer.Type: GrantFiled: July 31, 2000Date of Patent: January 24, 2006Assignee: Dabur Research FoundationInventors: Anand C. Burman, Sudhanand Prasad, Rama Mukherjee, Manu Jaggi, Anu T. Singh, Archna Mathur
-
Patent number: 6949513Abstract: A polypeptide of the formula (I), Pa-L-Pb-L-Pc-L-Pd.Type: GrantFiled: June 28, 2002Date of Patent: September 27, 2005Assignee: Dabur Research FoundationInventors: Sudhanand Prasad, Rama Mukherjee, Anand C. Burman, Archna Mathur, Rajan Sharma, Manu Jaggi
-
Patent number: 6828304Abstract: This invention relates to novel antiproliferative and anti secrectory peptides that are inhibitory to vasoactive intestinal peptide receptor and are useful in the treatment of cancer. The invention particularly relates to the synthesis of lipid-peptide conjugates containing fatty acids of different sizes, which inhibits the binding of VIP to its receptors. The invention encompasses methods for generation of these peptides, composition containing these peptides and the pharmacological applications of these peptides especially in the treatment and prevention of cancer.Type: GrantFiled: July 31, 2000Date of Patent: December 7, 2004Assignee: Dabur Research FoundationInventors: Anand C. Burman, Sudhanand Prasad, Rama Mukherjee, Manu Jaggi, Anu T. Singh, Rajan Sharma
-
Publication number: 20040121950Abstract: The present invention relates to a combination of peptides that may be used for treatment of cancer. The peptide combination competes for the binding of specific neuropeptides at the plasma membrane and thereby alters the levels of key intracellular molecules implicated in cell proliferation, resulting in a broad spectrum of anticancer activity. The invention also relates to pharmaceutical compositions containing a combination of such peptide analogs.Type: ApplicationFiled: December 23, 2002Publication date: June 24, 2004Applicant: DABUR RESEARCH FOUNDATIONInventors: Rama Mukherjee, Anand C. Burman, Anu T. Singh, Manu Jaggi, Sudhanand Prasad, Sarjana Dutt
-
Publication number: 20030229146Abstract: The invention relates to the use of derivatives of cyclopentenone for the inhibition or prevention of the growth or multiplication of cancer cells, and to therapeutic compositions containing such compounds.Type: ApplicationFiled: December 4, 2002Publication date: December 11, 2003Applicant: DABUR RESEARCH FOUNDATIONInventors: Mukund K. Gurjar, Radhika D. Wakharkar, Gautam R. Desiraju, Ashwini Nangia, J. S. Yadav, Anand C. Burman, Rama Mukherjee, Hanumant Bapurao Borate, Srivari Chandrasekhar, Manu Jaggi, Anuo T. Singh, Kamal K. Kapoor, Sanjay Sarkhel, Kalapatapu V.V.M. Sairam
-
Patent number: 6656970Abstract: The present invention provides compositions and methods for the solubilization of poorly soluble drugs such as triterpenes like betulinic acid and/its derivatives in pharmaceutically acceptable liquid vehicles that avoid use of potentially toxic solvents that are often used for the solubilization of poorly soluble drugs. In the compositions of this invention the drugs remain physically and chemically stable and can be administered intravascularly without undue toxicity from undissolved drug and/or from the solvent vehicles at a drug dose meant to be effective to exhibit clinically significant anticancer activity.Type: GrantFiled: March 8, 2001Date of Patent: December 2, 2003Assignee: Dabur Research FoundationInventors: Anand C. Burman, Rama Mukherjee, Honey Bala, Dhiraj Khattar